Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
921-940 of 1,782 trials

Ovarian Cancer: Olaparib and Durvalumab Study

We are exploring whether Olaparib alone or with Durvalumab can be safely given to patients with high-grade ovarian cancer before surgery. This study may help us learn more about treatment effectiveness and safety.

Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Heart Attack Treatment: Timing of Medications

We are studying how the timing of beta blockers, ACE inhibitors, and SGLT2 inhibitors affects heart function in people who have had a heart attack. This may help us understand the best way to use these medications for better recovery.

Heart Attack>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Cardiogenic Shock: Beta Receptor Modulation Trial

We are testing a new approach to manage heart function in patients with cardiogenic shock on V-A ECMO. This study compares reducing beta receptor stimulation to the usual treatment to see which is safer and more effective.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Relapsed Multiple Myeloma: Daratumumab Treatment Study

We are comparing two treatment strategies using Daratumumab, Lenalidomide, and Dexamethasone for patients with relapsed multiple myeloma. The goal is to see if a fixed treatment duration is as effective as continuous therapy.

Myeloma Recurrence>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Baricitinib for Calcium Pyrophosphate Disease

We are studying whether Baricitinib can reduce inflammation and improve symptoms in people with calcium pyrophosphate dihydrate deposition disease. This trial will help us understand its effects on pain and inflammation.

Calcium Pyrophosphate Deposition Disease3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Antisynthetase Syndrome: Cyclophosphamide vs Tacrolimus

We are comparing the effects of Cyclophosphamide and Azathioprine against Tacrolimus in patients with antisynthetase syndrome-related lung disease. The goal is to see which treatment better improves lung function and quality of life.

Interstitial Lung DiseaseConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

Tremelimumab Injection for Early-Stage Lung Cancer

We are studying a new injection method for delivering tremelimumab to patients with early-stage non-small cell lung cancer. The goal is to evaluate its safety and how well it works in the body.

Non-small cell lung cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Macular Telangiectasia Type 1: Aflibercept vs. Placebo

We are studying whether aflibercept can improve retinal thickness and vision in patients with macular telangiectasia type 1 compared to a placebo. The trial also looks at the safety of the treatment.

Macular Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesOphthalmology

COPD Exacerbation: New Diagnostic Strategy

We are testing a new method using advanced diagnostics to see if it can help reduce antibiotic use during severe COPD flare-ups. This study compares this approach to standard treatment to evaluate its effectiveness and safety.

Severe COPD with Ventilation Support>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPulmonology

Dermatomyositis: Baricitinib Treatment Study

We are studying whether baricitinib can help patients with dermatomyositis improve without using steroids. This trial compares its effects to a placebo while providing usual care.

Dermatomyositis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesDermatologyRheumatology

Pancreatic Cancer: FOLFOX vs. Gemcitabine

We are comparing two chemotherapy treatments, FOLFOX and gemcitabine, for patients with advanced pancreatic cancer who cannot tolerate a stronger regimen. The goal is to see which treatment works better and is safer for these patients.

Pancreatic Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Pasireotide for Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

We are studying whether pasireotide can help patients with specific cancers live longer without their disease progressing. This trial focuses on those with synovial sarcoma and desmoplastic small round cell tumor.

Locally Advanced or Metastatic Synovial SarcomaLocally Advanced or Metastatic Desmoplastic Small Round Cell Tumor>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Postoperative Pain Relief After Hip Surgery: Intrathecal Morphine Study

We are testing whether intrathecal morphine, with or without a specific nerve block, can improve pain relief after total hip arthroplasty. This study aims to find the best way to manage pain during recovery.

Total Hip Replacement Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Cardiovascular Risk Management: BIO-RISK-EVENT Study

We are testing a new approach to managing heart health in patients at high risk for heart events. The goal is to see if this intensified treatment is more effective than standard care.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Oxygen Therapy for Acute Pulmonary Embolism

We are investigating whether supplemental oxygen helps patients with intermediate-risk acute pulmonary embolism improve their health and reduce hospital stays. The study also looks at its effects on survival rates over time.

Acute Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyPulmonology

Knee Osteoarthritis: Intra-Articular Clodronate Study

We are investigating whether different doses of clodronate can help reduce knee pain and improve function in people with painful knee osteoarthritis. The study will also monitor safety and tolerability of the treatment.

Knee Osteoarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Dapagliflozin for Decompensated Liver Cirrhosis

We are studying whether dapagliflozin is safe and effective for patients with decompensated liver cirrhosis compared to standard treatments. The trial also looks at how it may affect quality of life and various health markers.

Decompensated Liver Cirrhosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Mantle Cell Lymphoma: Pirtobrutinib and Rituximab Study

We are evaluating a new treatment combining pirtobrutinib and rituximab for patients with indolent Mantle Cell Lymphoma. The study aims to determine its effectiveness and safety compared to standard therapies.

Mantle Cell Lymphoma1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Pneumonia in Preschool Children: Amoxicillin Study

We are investigating whether amoxicillin helps preschool children with pneumonia compared to a placebo. The study also looks at how the antibiotic affects airway bacteria and other related factors.

Community Acquired Pneumonia>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteInfectious DiseasesPulmonology

Atezolizumab for Muscle-Invasive Bladder Cancer

We are studying whether atezolizumab can help patients with muscle-invasive bladder cancer who cannot have surgery after chemo-radiotherapy. The trial looks at how well it works and its impact on patients' quality of life.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology